EpiNess™ - Reinventing Epilepsy Management

EpiNess™ combines wearable EEG monitoring with automated analysis to support epilepsy monitoring at home.

Understanding Epilepsy

Epilepsy affects millions worldwide, with significant impact on quality of life and daily activities.

65 million

People worldwide live with epilepsy, making it one of the most common neurological disorders

30%

Approximately one in three people with epilepsy have seizures that are not controlled by medications (drug-resistant epilepsy)

Up to 3×

Higher risk of premature death in people with epilepsy compared to the general population

1 in 1,000

50,000 people with epilepsy die per year from SUDEP (Sudden Unexpected Death in Epilepsy)

$119 billion

Estimated annual global cost of epilepsy, including medical expenses and lost productivity

25%

Of the epilepsy patients suffer from depression, underscoring the substantial impact on mental health and quality of life

Our Solution

NeuroHelp's epilepsy monitoring platform combines wearable EEG with automated signal analysis.

Seizure Detection

Automated algorithms analyze brain activity patterns to identify potential seizure activity, supporting monitoring for patients and caregivers.

From Detection Toward Prediction

Beyond seizure detection, NeuroHelp is developing seizure prediction methods aimed at identifying EEG changes that may precede seizure activity. This capability is under development and forms part of NeuroHelp's long-term vision.

Epilepsy Detection System

Clinical Validation

Performance

  • General Population - 75% seizure detection rate with 1 false alarm in 5 days
  • Temporal Lobe Epilepsy Patients - Only 1 false alarm per month
  • Tonic-Clonic Seizures - Able to detect with 92% success without false alarms

Clinical Trials

  • Beilinson Hospital: Clinical validation of wearable device and detection algorithm including 30 patients (Started May 2025)
  • Sheba Medical Center: Software evaluation using clinical EEG data including 100 patients (Started May 2025)
  • Planned FDA Clinical Trials across multiple U.S. epilepsy clinics (Planned H2 2026)

Seize Control - Don’t Let Epilepsy Define You

Reach us and join our ongoing clinical trials or get the latest news on the development of EpiNess™.

Book a Demo